TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: CIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Symptom severity (NHLBI severity grade)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal awakenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence rate of MACE incidents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence rate of angina pectoris after infarct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: YKL-40 concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in daily step activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of myocardial perfusion and wall motion analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: seizure frequency reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in days of thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in days of neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevention of chemotherapy-induced alopecia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Glycated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial responses across multiple tumour types
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in MADRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in SDS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 4 neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Nutritional recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HV interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Localization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: emotional response to stimuli
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cost per death or impairment averted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Interpersonal Distrust
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interoceptive Awareness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maturity Fears
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: follow-up sequelae
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in HbA1c from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects reaching HbA1c < 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean QALYs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: event-free life expectancy
Endpoint domain: Mortality/survival
Primary endpoint: global anti-plaque efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality by 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Debilitating pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Total duration of radiofrequency energy needed to achieve isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: earlier entry into care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total drainage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Loss of cementum and dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to complete healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of patient-reported swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of patient-reported swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of patient-reported swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of colony-forming units in the solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful performance of fundus examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving iPTH ≤ 300 pg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Achieving serum P ≤ 4.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean mid-arm circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or severe disability
Endpoint domain: Mortality/survival
Primary endpoint: Peripheral Arterial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Caloric intake reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decreased minimum chair height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased hip extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of probable dementia
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of mild cognitive impairment (MCI)
Endpoint domain: Mortality/survival
Primary endpoint: mean blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post-prandial blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete resection rate for adenomatous polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Thrombotic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean distalization amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distalization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maxillary first molars tipping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (<200 copies/mL at week 24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or higher triglyceride increases
Endpoint domain: Adverse events/effects
Primary endpoint: Nonadherence to vision care guidelines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: active coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS-assessed hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS-assessed fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ad lib energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: UVB-SPF value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UVA-PF value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of once‐daily tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median lesion count reduction percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: median investigator‐assessed improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time without disease progression or adverse events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life adjusted time
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stroke or hard TIA within 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Any stroke or TIA within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Contraction torques for knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Contraction torques for elbow flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anxiety diagnosis free status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number and severity of attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ampoules of C1‐esterase inhibitor needed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity of urine 5-HIAA measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of urine 5-HIAA measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat-free mass accretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental health perceptions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Melasma Assessment Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of hopelessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: lightening of PWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: distant ipsilateral flares of toxicoderma-like eruptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: severe deterioration of experimental dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CD4+ cell count changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma viraemia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mobility angles of the injured knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall of words
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recognition of completed word fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cumulative rate of patients with recurrent subocclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: occlusion-free time interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: occlusion-free survival at 12, 24, and 36 months
Endpoint domain: Mortality/survival
Primary endpoint: Improvements in vitality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvements in general health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of midazolam vs diazepam in sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: GA growth rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urinary outcomes
Primary endpoint: incidence of pain/burning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient report of physicians' PDM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systolic BP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participation rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Caries progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malaria morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health literacy rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant satisfaction with the WeChat health education programme
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Headache incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Creatinine phosphokinase elevations
Endpoint domain: Adverse events/effects
Primary endpoint: Time required to replace drainage bags
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bags detached
Endpoint domain: Adverse events/effects
Primary endpoint: Patient and medical staff satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: myopic reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unaided high-contrast visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unaided low-contrast visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting brachial artery blood flow (BABF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brachial artery diameter (BAD) during peak hyperemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: illness severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of missed pills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient experiences of recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: device-oriented composite of cardiac death, target vessel-related myocardial infarction, or target lesion revascularisation
Endpoint domain: Mortality/survival
Primary endpoint: Self-reported functional ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of breast events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain threshold reduction after duodenal lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: isometric trunk muscles measurements improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: standing reach height improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMQ mean score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder pain awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: range of articular motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedative effects
Endpoint domain: Adverse events/effects
Primary endpoint: Left ventricular systolic volume index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Noninfarct myocardial fibrosis reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in serum biomarkers of systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: overall behavior scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Minimal Clinically Important Improvement (MCII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum bone specific alkaline phosphatase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Oxidative stress status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue antiemetics required
Endpoint domain: Adverse events/effects
Primary endpoint: self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Central macular thickness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of knowledge mean score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of maintenance self-care mean
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of management self-care mean
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of confidence self-care mean
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily cigarette consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acquisition of P aeruginosa infection
Endpoint domain: Adverse events/effects
Primary endpoint: chronic infection
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal diffusion in normal-appearing PYT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AH activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Paracetamol bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver function (cytochrome P450 1A2 activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child mean BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Receptor occupancy in high-binding regions of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average discomfort scores during tissue manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear scores during docking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvements in subjective visual symptoms from 1 to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motivation to change dietary habits
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motivation to change physical activity habits
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bothersomeness of bladder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urogenital Distress Inventory, Short Form score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence Impact Questionnaire, Short Form score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: scar appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of NWO (Normal Weight Obesity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Three-dimensional deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QUICKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Homoarginine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ADMA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HSV-2 acquisition
Endpoint domain: Mortality/survival
Primary endpoint: Mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2/FIO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean stay in the PICU
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Falls in NO from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recovery of peripheral platelet counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of chemotherapy postponements due to myelotoxicity
Endpoint domain: Adverse events/effects